Status:
COMPLETED
A Study of ARRY-520 in Patients With Advanced Cancer
Lead Sponsor:
Array Biopharma, now a wholly owned subsidiary of Pfizer
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-520. This study has two parts. In the first part, patients with advanced solid tu...
Eligibility Criteria
Inclusion
- Key
- Histological or cytological evidence of malignancy.
- Advanced solid tumors that have recurred or progressed following standard therapy(ies).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Adequate hematology counts and serum chemistry values.
- Additional criteria exist.
- Key
Exclusion
- Treatment with an investigational product or device, or anti-neoplastic therapy (with the exclusion of hormone therapy where the therapy will continue at a standard dose throughout the study) within 28 days prior to the first dose of study drug.
- Major surgery within 28 days prior to the first dose of study drug.
- Radiotherapy (RT) within 28 days prior to the first dose of study drug (except if local RT to \<5% of the bone marrow).
- Known positive serology for the human immunodeficiency virus (HIV), hepatitis C, and/or active hepatitis B.
- Additional criteria exist.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00462358
Start Date
April 1 2007
End Date
November 1 2010
Last Update
September 28 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland, United States, 21201
2
Wayne State University, Karmanos Cancer Institute
Detroit, Michigan, United States, 48201